The development of a highly selective 5‐HT1 receptor agonist, sumatriptan, for the treatment of migraine

Drug Development Research

Volumn 26, Issue 3, 1992, Pages 235-240

  Feniuk, Wasyl ^a   Humphrey, Patrick P A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 HT1 agonists; migraine; sumatriptan

Indexed keywords

SEROTONIN 1 RECEPTOR; SUMATRIPTAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; MIGRAINE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VASOCONSTRICTION;

EID: 0026633429     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.430260304     Document Type: Article

References (41)

1. Evidence for two types of excitatory receptor for 5‐hydroxytryptamine in dog isolated vasulature
2. The antimigraine drug sumatriptan (GR43175) selectively blocks neurogenic plasma extravasation from blood vessels in dura mater
3. Further characterisation of the putative 5‐HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater
4. Dihydroergotamine and sumatriptan attenuate the increase in plasma calcitonin gene related peptide levels within rat superior saggittal sinus during electrical trigeminal ganglion stimulation
5. Treatment of acute migraine with subcutaneous sumatriptan
6. 1‐like receptor agonist
7. 1‐like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan
8. What is migraine? Controversy and stalemate in migraine pathophysiology
9. Mechanisms of 5‐hydroxytryptamine‐induced vasoconstriction
10. CG43175 does not share the complex pharmacology of the ergots
11. The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetised dogs
12. 1‐like agonists in the treatment of migraine
13. Migraine pain associated with middle cerebral dilatation: Reversal by sumatriptan
14. Sumatriptan reverses the changes in calcitonin gene‐related peptide seen in the headache phase of migraine
15. Mechanism of migraine headache and action of ergotamine tartrate
16. Pathogenesis of migraine
17. 5‐Hydroxytryptamine and the pathophysiology of migraine
18. 1‐like receptor in dog isolated saphenous vein
19. 1‐like receptor agonist GR43175
20. The vasoconstrictor action of sumatriptan on human isolated dura mater
21. Preclinical studies on the anti‐migraine drug, sumatriptan
22. Effect of sumatriptan on pial vessel diameter in vivo
23. The macro and microvasculature of the dura mater
24. Effect of serotonin in migraine patients
25. The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome
26. Serotonin, the carotid body and cranial vessels in migraine
27. Neurobiology of vascular head pain
28. Neuroeffector functions of sensory fibres: Implications for headache mechanisms and drug actions
29. Focal headache during balloon inflation in the internal carotid and middle cerebral arteries
30. 1‐like receptors mediate 5‐hydroxytryptamine‐induced contraction of human isolated basilar artery
31. Clinical experience with oral sumatriptan: A placebo controlled, dose‐ranging study
32. 1D binding sites
33. The selective closure of feline carotid arteriovenous anastomoses by GR43175
34. Experimental studies on headache: Pain‐sensitive structures of the head and their significance in headache
35. Selective vasoconstriction in carotid vascular bed by methysergide: Possible relevance to its antimigraine effect
36. Lack of antinociceptive activity of sumatriptan in rodents
37. In vivo effects of sumatriptan (GR43175) on extracellular levels of 5‐HT in the guinea pig
38. Responsiveness of isolated cerebral and peripheral arteries to serotonin, norepinephrine and transmural electrical stimulation
39. The concept of selectivity in 5‐HT receptor research
40. A prefunctional action of 5‐hydroxytryptamine and methysergide on noradrenergic nerves in dog isolated saphenous vein